Latest Breaking News On - Persistent corneal epithelial defect - Page 1 : comparemela.com

Kiora Pharmaceuticals, Inc : Kiora Pharmaceuticals KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects

In a second presentation, Kiora shared additional positive results for its KIO-100 platform in the treatment of autoimmune uveitis. Encinitas, California (Newsfile Corp. - April 26, 2023) - Kiora Pharmaceuticals

Brianm stremFrancina agostiEnriqueo graue hernandezCalifornia newsfile corpKiora pharmaceuticalsAssociation for researchPersistent corneal epithelial defectsChemically modified formHyaluronic acidImproves wound healingPersistent corneal epithelial defectPrincipal investigatorOcular presentationRheumatoid arthritisDihydroorotate dehydrogenasePrivate securities litigation reform act

Kiora Pharmaceuticals (KPRX) KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects

Kiora Pharmaceuticals (KPRX) KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Enriqueo graue hernandezBrianm stremAssociation for researchKiora pharmaceuticalsWall streetPersistent corneal epithelial defectsChemically modified formHyaluronic acidImproves wound healingPersistent corneal epithelial defectPrincipal investigator

Kala Pharmaceuticals (KALA) Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals (KALA) Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKim brazzellDrug administrationKala pharmaceuticals incKala pharmaceuticalsChief medical officerBiologics license applicationPersistent corneal epithelial defect

Kala Pharmaceuticals Shares Jump Nearly 20% on News of IND, Private Placement

Kala Pharmaceuticals Shares Jump Nearly 20% on News of IND, Private Placement
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

Stephen nakrosisDow jones company incDrug administrationKala pharmaceuticals incKala pharmaceuticalsPersistent corneal epithelial defectDow jones

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing,. | November 28, 2022

United statesMark iwickiHannah deresiewiczExchange commissionDrug administrationKala pharmaceuticals incKala pharmaceuticalsGlobenewswire incPersistent corneal epithelial defectBiologics license agreementChief executive officerMesenchymal stem cell secretomePartial limbal stem cell deficiencyLooking statementsPrivate securities litigation reform actNasdaq global select market